المؤلفون: Chari A; Icahn School of Medicine at Mount Sinai, New York, NY, USA. ajai.chari@ucsf.edu., Kaufman JL; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Laubach J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Sborov DW; Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA., Reeves B; University of North Carolina-Department of Medicine-Chapel Hill, Chapel Hill, NC, USA., Rodriguez C; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Silbermann R; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Costa LJ; University of Alabama at Birmingham, Birmingham, AL, USA., Anderson LD Jr; Myeloma, Waldenstrӧm's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Nathwani N; Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Shah N; University of California San Francisco, San Francisco, CA, USA., Bumma N; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Holstein SA; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Costello C; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA., Jakubowiak A; University of Chicago Medical Center, Chicago, IL, USA., Wildes TM; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Cowan AJ; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA, USA., Pei H; Janssen Research & Development, LLC, Titusville, NJ, USA., Cortoos A; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Patel S; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Lin TS; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Voorhees PM; Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, USA. Peter.Voorhees@atriumhealth.org., Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org., Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

المصدر: Blood cancer journal [Blood Cancer J] 2024 Jul 08; Vol. 14 (1), pp. 107. Date of Electronic Publication: 2024 Jul 08.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Multicenter Study

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/mortality , Multiple Myeloma*/therapy , Multiple Myeloma*/diagnosis , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Aged ; Female ; Male ; Middle Aged ; Adult ; Dexamethasone/administration & dosage ; Dexamethasone/therapeutic use ; Bortezomib/therapeutic use ; Bortezomib/administration & dosage ; Lenalidomide/therapeutic use ; Lenalidomide/administration & dosage

المؤلفون: Silbermann R; Division of Hematology/Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA., Laubach J; Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA., Kaufman JL; Department of Mematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Sborov DW; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah, USA., Reeves B; Division of Hematology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA., Rodriguez C; Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA., Chari A; Department of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, New York, USA., Costa LJ; Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA., Anderson LD Jr; Division of Hematology/Oncology, Simmons Comprehensive Cancer Center, UT Texas Southwestern Medical Center, Dallas, Texas, USA., Nathwani N; Division of Myeloma, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA., Shah N; Department of Medicine, University of California San Francisco, San Francisco, California, USA., Bumma N; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA., Holstein SA; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, Nebraska, USA., Costello C; Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, California, USA., Jakubowiak A; Medicine- Hematology and Oncology, University of Chicago, Chicago, Illinois, USA., Orlowski RZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Cowan AJ; Department of Medicine, University of Washington, Seattle, Washington, USA., Gries KS; Janssen Research & Development, Raritan, New Jersey, USA., Pei H; Janssen Research & Development, LLC, Titusville, New Jersey, USA., Cortoos A; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Patel S; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Lin TS; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Voorhees PM; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health/Wake Forest University School of Medicine, Charlotte, North Carolina, USA., Usmani SZ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Richardson PG; Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA.

المصدر: American journal of hematology [Am J Hematol] 2024 Jul; Vol. 99 (7), pp. 1257-1268. Date of Electronic Publication: 2024 Apr 15.

نوع المنشور: Journal Article; Clinical Trial, Phase II; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Quality of Life* , Bortezomib*/administration & dosage , Bortezomib*/therapeutic use , Dexamethasone*/administration & dosage , Dexamethasone*/therapeutic use , Lenalidomide*/administration & dosage , Lenalidomide*/therapeutic use , Patient Reported Outcome Measures* , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult

المؤلفون: Zanwar S; Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA., Sidana S; Stanford University School of Medicine, Stanford, CA, USA., Shune L; The University of Kansas Medical Center, Kansas City, KS, USA., Puglianini OC; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Pasvolsky O; Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gonzalez R; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Dima D; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA., Afrough A; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Kaur G; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Davis JA; Medical University of South Carolina, Charleston, SC, USA., Herr M; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Hashmi H; Medical University of South Carolina, Charleston, SC, USA.; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Forsberg P; University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Sborov D; The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Anderson LD Jr; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., McGuirk JP; The University of Kansas Medical Center, Kansas City, KS, USA., Wagner C; The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Lieberman-Cribbin A; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Rossi A; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Freeman CL; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Locke FL; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Richard S; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Khouri J; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA., Lin Y; Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA., Patel KK; Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. KPatel1@mdanderson.org., Kumar SK; Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. Kumar.Shaji@mayo.edu., Hansen DK; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Doris.Hansen@moffitt.org.

المصدر: Journal of hematology & oncology [J Hematol Oncol] 2024 Jun 06; Vol. 17 (1), pp. 42. Date of Electronic Publication: 2024 Jun 06.

نوع المنشور: Letter; Multicenter Study; Journal Article

بيانات الدورية: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over ; Tissue Extracts/therapeutic use ; Treatment Outcome ; Biological Products/therapeutic use ; Retrospective Studies ; Immunotherapy, Adoptive/methods ; Progression-Free Survival ; Receptors, Chimeric Antigen

المؤلفون: Khouri J; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Dima D; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio. Electronic address: dimad@ccf.org., Li H; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Hansen D; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Sidana S; Stanford University School of Medicine, Stanford, California., Shune L; University of Kansas Medical Center, Kansas City, Kansas., Anwer F; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Sborov D; University of Utah Huntsman Cancer Institute, Salt Lake City, Utah., Wagner C; University of Utah Huntsman Cancer Institute, Salt Lake City, Utah., Kocoglu MH; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland., Atrash S; Levine Cancer Institute, Charlotte, North Carolina., Voorhees P; Levine Cancer Institute, Charlotte, North Carolina., Peres L; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Hovanky V; Stanford University School of Medicine, Stanford, California., Simmons G; Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia., Williams L; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Raza S; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Afrough A; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas., Anderson LD Jr; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas., Ferreri C; The University of Texas MD Anderson Cancer Center, Houston, Texas., Hashmi H; Medical University of South Carolina, Charleston, South Carolina., Davis J; Medical University of South Carolina, Charleston, South Carolina., McGuirk J; University of Kansas Medical Center, Kansas City, Kansas., Goldsmith S; City of Hope Cancer Center, Duarte, California., Borogovac A; City of Hope Cancer Center, Duarte, California., Lin Y; Mayo Clinic Cancer Center, Rochester, Minnesota., Midha S; Dana-Farber Cancer Institute, Boston, Massachusetts., Nadeem O; Dana-Farber Cancer Institute, Boston, Massachusetts., Locke FL; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Baz R; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Hamilton B; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Alsina M; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida., Sauter C; Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio., Patel K; The University of Texas MD Anderson Cancer Center, Houston, Texas., Kaur G; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas.

المصدر: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Jun 02. Date of Electronic Publication: 2024 Jun 02.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE

المؤلفون: Nooka AK; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Kaufman JL; Winship Cancer Institute, Emory University, Atlanta, Georgia, USA., Rodriguez C; Icahn School of Medicine at Mount Sinai, New York, New York, USA., Jakubowiak A; University of Chicago Medical Center, Chicago, Illinois, USA., Efebera Y; OhioHealth, Columbus, Ohio, USA., Reeves B; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Wildes TM; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA., Holstein SA; Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA., Anderson LD Jr; Myeloma, Waldenström's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Badros A; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, Maryland, USA., Shune L; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA., Chari A; Icahn School of Medicine at Mount Sinai, New York, New York, USA.; University of California at San Francisco, San Francisco, California, USA., Pei H; Janssen Research & Development, LLC, Titusville, New Jersey, USA., Cortoos A; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Patel S; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Lin TS; Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, USA., Voorhees PM; Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, North Carolina, USA., Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Richardson PG; Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA.

المصدر: British journal of haematology [Br J Haematol] 2024 Jun; Vol. 204 (6), pp. 2227-2232. Date of Electronic Publication: 2024 Mar 19.

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Lenalidomide*/administration & dosage , Lenalidomide*/adverse effects , Lenalidomide*/therapeutic use , Dexamethasone*/administration & dosage , Dexamethasone*/adverse effects , Dexamethasone*/therapeutic use , Bortezomib*/administration & dosage , Bortezomib*/adverse effects , Bortezomib*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Multiple Myeloma*/drug therapy , Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/adverse effects , Antibodies, Monoclonal*/therapeutic use, Humans ; Female ; Male ; Middle Aged ; Aged ; Adult ; Black or African American

المؤلفون: Lin Y; Department of Hematology, Mayo Clinic, Rochester, MN, USA. Electronic address: lin.yi@mayo.edu., Qiu L; Institution of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China., Usmani S; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Joo CW; Department of Medical Oncology, National University Cancer Institute, Singapore., Costa L; Department of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA., Derman B; Department of Hematology and Oncology, University of Chicago, Chicago, IL, USA., Du J; Shanghai Changzheng Hospital, Shanghai, China., Einsele H; Department of Internal Medicine II, University Hospital, Wurzburg, Germany., Fernandez de Larrea C; Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Hajek R; Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic; Department of Hematooncology, Faculty of Medicine, University Ostrava, Ostrava, Czech Republic., Ho PJ; Institute of Hematology, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia., Kastritis E; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Alexandra General Hospital, Athens, Greece., Martinez-Lopez J; Hospital Universitario 12 de Octubre, Department of Medicine, Complutense University, CNIO, Madrid, Spain., Mateos MV; Hospital Universitario de Salamanca, Salamanca, Spain., Mikhael J; Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA., Moreau P; Department of Hematology, University Hospital of Nantes, Nantes, France., Nagarajan C; Department of Haematology, Singapore General Hospital, Singapore., Nooka A; Winship Cancer Institute of Emory University, Atlanta, GA, USA., O'Dwyer M; Department of Medicine and Department of Haematology, National University of Ireland, Galway, Ireland., Schjesvold F; Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway., Sidana S; Department of Hematology, Stanford University, Standford, CA, USA., van de Donk NW; Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands., Weisel K; Wilhelminen Cancer Research Institute, First Department of Medicine, Clinic Ottakring, Vienna, Austria., Zweegman S; Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands., Raje N; Department of Medicine, Harvard University, Cambridge, MA, USA., Otero PR; Department of Hematology, Cancer Center Clinica Universidad de Navarra, Pamplona, Navarra, Spain., Anderson LD Jr; Simmons Comprehensive Cancer Center, Dallas, TX, USA; University of Texas Southwestern Medical Center, Dallas, TX, USA., Kumar S; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Martin T; Department of Hematology, University of California, San Francisco, CA, USA.

مؤلفون مشاركون: International Myeloma Working Group

المصدر: The Lancet. Oncology [Lancet Oncol] 2024 May 28. Date of Electronic Publication: 2024 May 28.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

المؤلفون: Afrough A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Abraham PR; Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Turer L; Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Kaur G; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Sannareddy A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA., Hansen DK; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Anderson LD Jr; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.

المصدر: Acta haematologica [Acta Haematol] 2024 May 08, pp. 1-15. Date of Electronic Publication: 2024 May 08.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Karger Country of Publication: Switzerland NLM ID: 0141053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1421-9662 (Electronic) Linking ISSN: 00015792 NLM ISO Abbreviation: Acta Haematol Subsets: MEDLINE

المؤلفون: Hashmi H; Medical University of South Carolina., Hansen DK; H. Lee Moffitt Cancer Center and Research Institute., Peres LC; H. Lee Moffitt Cancer Center and Research Institute., Puglianini OC; H. Lee Moffitt Cancer Center and Research Institute., Freeman C; H. Lee Moffitt Cancer Center and Research Institute., De Avila G; H. Lee Moffitt Cancer Center and Research Institute., Sidana S; Stanford University School of Medicine., Shune L; The University of Kansas Medical Center., Sborov DW; The University of Utah Huntsman Cancer Institute., Davis J; Medical University of South Carolina., Wagner C; The University of Utah Huntsman Cancer Institute., Kocoglu MH; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center., Atrash S; Levine Cancer Institute., Voorhees P; Levine Cancer Institute., Simmons G; Virginia Commonwealth University Massey Cancer Center., Ferreri C; The University of Texas MD Anderson Cancer Center., Kalariya N; The University of Texas MD Anderson Cancer Center., Anderson LD Jr; UT Southwestern Harold C. Simmons Comprehensive Cancer Center., Afrough A; UT Southwestern Harold C. Simmons Comprehensive Cancer Center., Dima D; Cleveland Clinic, Cleveland, OH., Khouri J; Cleveland Clinic, Cleveland, OH., McGuirk J; The University of Kansas Medical Center., Locke F; H. Lee Moffitt Cancer Center and Research Institute., Baz R; H. Lee Moffitt Cancer Center and Research Institute., Patel KK; The University of Texas MD Anderson Cancer Center., Alsina M; H. Lee Moffitt Cancer Center and Research Institute.

المصدر: Haematologica [Haematologica] 2024 May 01; Vol. 109 (5), pp. 1514-1524. Date of Electronic Publication: 2024 May 01.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Multicenter Study

بيانات الدورية: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/therapy , Multiple Myeloma*/immunology , Multiple Myeloma*/mortality , Immunotherapy, Adoptive*/methods , Immunotherapy, Adoptive*/adverse effects , Disease Progression*, Humans ; Male ; Female ; Middle Aged ; Aged ; Biological Products/therapeutic use ; Biological Products/administration & dosage ; Adult ; B-Cell Maturation Antigen/immunology ; Antigens, CD19/immunology ; Antigens, CD19/therapeutic use ; Recurrence ; Treatment Outcome ; Aged, 80 and over ; Drug Resistance, Neoplasm ; United States/epidemiology ; Recombinant Fusion Proteins/administration & dosage ; Recombinant Fusion Proteins/therapeutic use ; Receptors, Chimeric Antigen/immunology ; Receptors, Chimeric Antigen/therapeutic use ; Risk Factors

المؤلفون: Hydren JR; HealthTree Foundation, Lehi, UT, United States., Lin D; Janssen Scientific Affairs, LLC, Horsham, PA, United States., Sweeney NW; HealthTree Foundation, Lehi, UT, United States., Wu B; Janssen Scientific Affairs, LLC, Horsham, PA, United States., Kim N; Janssen Scientific Affairs, LLC, Horsham, PA, United States., Patel S; Janssen US Oncology Medical Affairs, Horsham, PA, United States., Sborov DW; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States., Berdeja JG; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, United States., Anderson LD Jr; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States., Huo S; Janssen Scientific Affairs, LLC, Horsham, PA, United States., Hurtado Martínez JA; HealthTree Foundation, Lehi, UT, United States., Ahlstrom JM; HealthTree Foundation, Lehi, UT, United States.

المصدر: Frontiers in health services [Front Health Serv] 2024 Apr 24; Vol. 4, pp. 1354760. Date of Electronic Publication: 2024 Apr 24 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 9918334887706676 Publication Model: eCollection Cited Medium: Internet ISSN: 2813-0146 (Electronic) Linking ISSN: 28130146 NLM ISO Abbreviation: Front Health Serv Subsets: PubMed not MEDLINE

المؤلفون: Callander NS; University of Wisconsin Carbone Cancer Center, Madison, WI, USA. nsc@medicine.wisc.edu., Silbermann R; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Kaufman JL; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Godby KN; University of Alabama at Birmingham Hospital, Birmingham, AL, USA., Laubach J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Schmidt TM; University of Wisconsin Carbone Cancer Center, Madison, WI, USA., Sborov DW; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Medvedova E; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Reeves B; Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Dhakal B; Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA., Rodriguez C; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Chhabra S; Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA., Chari A; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Bal S; University of Alabama at Birmingham Hospital, Birmingham, AL, USA., Anderson LD Jr; Myeloma, Waldenstrӧm's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Dholaria BR; Vanderbilt University Medical Center, Nashville, TN, USA., Nathwani N; Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Hari P; Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA., Shah N; Department of Medicine, University of California San Francisco, San Francisco, CA, USA., Bumma N; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Holstein SA; Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Costello C; Moores Cancer Center, University of California San Diego, La Jolla, CA, USA., Jakubowiak A; University of Chicago Medical Center, Chicago, IL, USA., Wildes TM; Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA., Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Cowan AJ; Division of Medical Oncology, University of Washington, Seattle, WA, USA., Pei H; Janssen Research & Development, LLC, Titusville, NJ, USA., Cortoos A; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Patel S; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Lin TS; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Giri S; Division of Hematology & Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA., Costa LJ; University of Alabama at Birmingham Hospital, Birmingham, AL, USA., Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org., Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Voorhees PM; Levine Cancer Institute, Atrium Health Wake Forest Baptist, Charlotte, NC, USA. Peter.Voorhees@atriumhealth.org.

المصدر: Blood cancer journal [Blood Cancer J] 2024 Apr 22; Vol. 14 (1), pp. 69. Date of Electronic Publication: 2024 Apr 22.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Randomized Controlled Trial

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/genetics , Multiple Myeloma*/therapy , Multiple Myeloma*/mortality , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Female ; Male ; Middle Aged ; Aged ; Chromosome Aberrations ; Adult ; Lenalidomide/therapeutic use ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/therapeutic use